Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 3 trial found sacituzumab tirumotecan (sac-TMT) cut the risk of death by 32% and extended survival by 7 months compared to chemotherapy in patients with advanced or recurrent endometrial cancer. Presented at ESMO 2026 and published in The Lancet, the results are being hailed as a potential new standard of care. The FDA has the drug under priority review, with a decision expected by June 2027.
A major phase 3 trial has put sacituzumab tirumotecan (sac-TMT) on the map as a potential new standard of care for patients with advanced or recurrent endometrial cancer who've already been through platinum-based chemo and immunotherapy — a group with very few effective options left.
The TroFuse-005 trial, presented at the 2026 ESMO Congress and published in The Lancet, enrolled 776 patients and showed sac-TMT — a TROP2-targeting antibody-drug conjugate (ADC) — significantly outperformed physician's choice of chemotherapy on every major endpoint. The FDA has accepted a priority review application for the drug, with a decision targeted for June 15, 2027.
By the Numbers:
Why it matters: Endometrial cancer mortality has been rising ~1.6% annually, and patients who progress after chemo and immunotherapy have a median PFS of just 3–4 months on subsequent treatment. Sac-TMT offers a meaningful survival benefit for this underserved population, though its toxicity profile — particularly stomatitis and anemia — will require careful management in clinical practice.
